Clinical Trial Update: Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating daratumumab or the FMS inhibitor JNJ-40346527 given before surgery in high-risk localized or locally advanced prostate cancer; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Daratumumab (daratumumab)
• JNJ-40346527

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 1 | Status: COMPLETED